1. Scrip
  2. >>Business
  3. >>Deals

Merck Buys Into Orna's Circular RNA Platform With Emphasis On Vaccines

 
• By Jessica Merrill

Orna is retaining full ownership of its "crown jewel," in situ CAR programs for cancer. CEO Tom Barnes talked to Scrip about the deal and Orna's business strategy.

circles
Orna thinks circular RNA will present new drug therapeutics and vaccines • Source: Shutterstock

Orna Therapeutics, Inc. has clinched its first big pharma partner for its novel circular RNA (oRNA) technology platform in a deal with Merck & Co., Inc., but the start-up is retaining its lead programs, in situ chimeric antigen receptor (CAR) therapies (isCARs).

In an early-stage deal announced on 16 August, Merck agreed to pay Orna $150m up front and invest an additional...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Scrip M&A Podcast: What’s Next For Dealmaking In The Obesity Space?

 
• By Joseph Haas

With Sidley attorney Robert Darwin and EY economic analyst Arda Ural, Scrip looked at recent deals, the potential for more deals in the obesity space, and what type of assets might be most in demand.

Pfizer ‘Unwavering’ In Pursuit Of Metsera

 
• By Jessica Merrill

The big pharma remains committed to buying Metsera, even as the acquisition price has grown and some analysts pressed management on the value of the deal.

Pfizer’s And Novo’s Competing Bids For Metsera Devolve Into Lawsuits, Name Calling

 
• By Mandy Jackson

Pfizer filed another lawsuit to halt Novo Nordisk’s attempt to acquire obesity drug developer Metsera instead of the US big pharma. Novo said Pfizer’s legal actions are “without merit” and “desperate.”

More from Business

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

Korean Biosimilars Giants Step Up Race To Become Innovators

 
• By Jung Won Shin

South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.

AstraZeneca Stays Coy On US Pricing Deal Impact

 
• By Andrew McConaghie

Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.